|
Nov 10
|
How AI-enabled KPIs can help leaders align their companies—and get better results
|
|
Nov 10
|
Q3 2023 Exscientia PLC Earnings Call
|
|
Nov 9
|
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
|
|
Nov 8
|
Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Sanofi Probed for Market Manipulation by French Authorities
|
|
Nov 7
|
French prosecutors examine claims of market manipulation against Sanofi
|
|
Nov 7
|
UPDATE 1-French prosecutors probe Sanofi over possible market manipulation -source
|
|
Nov 6
|
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
|
|
Nov 5
|
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
This Stock Just Dropped By 15%: Is It a Buy?
|
|
Nov 2
|
Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline
|
|
Nov 2
|
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
|
|
Nov 2
|
Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results
|
|
Nov 1
|
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
|
|
Sep 29
|
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs
|
|
Sep 27
|
Amazon Health: A long play and a search for partners
|
|
Sep 26
|
FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
|
|
Sep 26
|
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
|
|
Sep 26
|
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
|
|
Sep 25
|
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
|